Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2019-01-28
2023-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Restriction Pressure on Muscle Damage Responses to Blood Flow Restriction Exercise
NCT05037942
Muscle Activation With Acute Bouts of Blood Flow Restricted Resistance Exercise
NCT05586451
The Effects of Lower Extremity Blood Flow Restriction Training on Power, and Muscle Size.
NCT03983070
Investigating Proximal Muscle Strength Effects by Incorporating Proximal Muscle Lengthening
NCT05710757
Resistance Exercise Blood Flow Restriction
NCT06724458
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low Load Resistance Exercise
Subjects allocated to Low Load Resistance Exercise will undergo 6 weeks of single-legged low load (25%) resistance exercise. Their contralateral leg will serve as within subject control.
Low Load Resistance Exercise
Subjects allocated to Low Load Resistance Exercise will undergo 6 weeks of single-legged low load (25%) resistance exercise. Subjects will then perform 4 sets of 30, 15, 15 and 15 repetitions at 25% of their 1RM for the single-legged leg press and single-legged knee extensions. Their contralateral leg will serve as within subject control.
Low Load Resistance Exercise + BFR
Subjects allocated to Low Load Resistance Exercise + BFR will undergo 6 weeks of single-legged low load (25%) resistance exercise plus blood flow restriction. Their contralateral leg will serve as within subject control.
Low Load Resistance Exercise + BFR
Subjects allocated to Low Load Resistance Exercise + BFR will undergo 6 weeks of single-legged low load (25%) resistance exercise with blood flow restriction (60% occlusion pressure). Subjects will then perform 4 sets of 30, 15, 15 and 15 repetitions at 25% of their 1RM for the single-legged leg press and single-legged knee extensions. Their contralateral leg will serve as within subject control.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low Load Resistance Exercise
Subjects allocated to Low Load Resistance Exercise will undergo 6 weeks of single-legged low load (25%) resistance exercise. Subjects will then perform 4 sets of 30, 15, 15 and 15 repetitions at 25% of their 1RM for the single-legged leg press and single-legged knee extensions. Their contralateral leg will serve as within subject control.
Low Load Resistance Exercise + BFR
Subjects allocated to Low Load Resistance Exercise + BFR will undergo 6 weeks of single-legged low load (25%) resistance exercise with blood flow restriction (60% occlusion pressure). Subjects will then perform 4 sets of 30, 15, 15 and 15 repetitions at 25% of their 1RM for the single-legged leg press and single-legged knee extensions. Their contralateral leg will serve as within subject control.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
4. Body Mass Index (BMI) between 18.5-30 kg/m2 inclusive
5. No medical condition that would limit their participation in supervised exercise training based on the Physical Activity Readiness Questionnaire for Everyone (PARQ+)
6. No current prescription medications, with the exception of birth control
7. Willing to allow researchers to use data, biospecimens (e.g., blood) and images (e.g., Dual Energy x-Ray Absorptiometry) for research purposes after study participation is completed
1. Evidence or self-report being pregnant, lactating, or anticipating becoming pregnant in the next year
2. Participation in resistance or aerobic exercise training \> 2 days per week within the 3 months prior to screening
3. Self-report of history of type 1 or 2 diabetes mellitus
4. Self-report history of cardiovascular, peripheral vascular, cerebral vascular, pulmonary, or renal disease
5. Self-report or evidence of uncontrolled hypertension
6. Self-report history of blood clotting disorders
7. Self-report history of deep vein thrombosis or pulmonary embolism
8. Self-report history of sickle cell trait
9. Self-report history of varicose veins
10. Self-report history of a myopathy leading to muscle loss, weakness, severe cramps or myalgia
11. Self-report history of orthopedic limitations that would preclude them from participation in a dynamic exercise program
12. Self-report history of musculoskeletal disorders (e.g., severe osteoarthritis, rheumatoid arthritis, avascular necrosis or osteonecrosis)
13. Self-report history of neurological disorders (e.g., peripheral neuropathy, amyotrophic lateral sclerosis, multiple sclerosis, fibromyalgia, Parkinson's disease)
14. Weight loss of \> 10% in the last 3 months prior to screening
15. Active smoking
16. Current consumption of \> 14 alcoholic drinks per week based on self-report
17. Absolute Contraindication to Exercise as Defined by the American College of Sports Medicine,1 including:
1. Resting diastolic blood pressure \> 100 mm Hg
2. Resting systolic blood pressure \> 180 mm Hg
3. Resting heart rate \> 100 beats per min
18. Self-report acute viral or bacterial upper or lower respiratory infection at screening
19. Any other condition that in the judgement of the Principal Investigator and/or the Medical Director of this protocol may interfere with study participation and adherence to the protocol
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Delfi, Inc.
UNKNOWN
Louisiana State University and A&M College
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Brian Irving
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brian Irving, PhD
Role: PRINCIPAL_INVESTIGATOR
Louisiana State University - Kinesiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lousiana State University
Baton Rouge, Louisiana, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB#3934
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.